Men's Health News

RSS

Research may help develop new therapies for aggressive prostate cancer

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

9 Nov 2010

New research shows psychoprophylaxis can help tocophobic men

New research, presented in a doctoral thesis from the Swedish medical university Karolinska Institutet, shows that psychoprophylaxis can help men with tocophobia (fear of childbirth).

9 Nov 2010

New approach to treat castration resistant prostate cancer

9 Nov 2010

Study confirms defect in sweat gland function as disease biomarker for XLHED

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia.

9 Nov 2010

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

The Centers for Medicare & Medicaid Services are conducting an unusual review to determine whether the government should pay for an expensive new vaccine for treating prostate cancer, rekindling debate over whether some therapies are too costly.

9 Nov 2010

Soy-based drug could prevent prostate cancer metastasis

Northwestern Medicine researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University have found that a new, nontoxic drug made from a chemical in soy could prevent the movement of cancer cells from the prostate to the rest of the body.

8 Nov 2010

Potential new biomarkers for very early prostate cancer

A new study presented at the National Cancer Research Institute (NCRI) conference in Liverpool next week has found potential new biomarkers for very early prostate cancer in men with no symptoms of the disease.

8 Nov 2010

NCRI launches first virtual biobank for prostate cancer research

The first virtual biobank dedicated to prostate cancer research has been launched today by the National Cancer Research Institute (NCRI). The UK Prostate Cancer Sample Collection Database will house details of around 10,000 biological samples taken from men in the UK with and without prostate cancer.

8 Nov 2010

Radiotherapy can benefit men with high risk prostate cancer: Research

Men treated with radiotherapy as well as hormone therapy for advanced prostate cancer were 43 per cent less likely to die from the disease, according to trial results presented at the NCRI Cancer Conference in Liverpool today (Monday).

8 Nov 2010

Testosterone treatment for frailty in older men lacks long term benefits

The beneficial effects of six months of testosterone treatment on muscle mass, strength and quality of life in frail elderly men are not maintained at six months post-treatment, according to a study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 Nov 2010

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known as salvage radiation therapy. Researchers at Fox Chase have now determined a better way to monitor outcomes after this procedure.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.

4 Nov 2010

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

When Medicare policy changes led to reductions in reimbursement for hormonal treatment of prostate cancer, there was a sharp decline in its use among patients not likely to benefit from the treatment. But among patients for whom the therapy is clearly beneficial, doctors continued to prescribe it at the same rate, according to a new study.

4 Nov 2010

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, announced today the publication of 10-year outcome data showing that PROSTASCINT (capromab pendetide) fusion imaging is an effective tool for targeting and guiding the dosing of prostate cancer radiotherapy.

3 Nov 2010

AHRQ study finds prostate cancer mortality rate declines by 45%

According to the U.S. Agency for Healthcare Research and Quality (AHRQ), compared to men in 1999, American men in 2006 that were fighting prostate cancer were 45% less likely to die from the disease.

3 Nov 2010

Image Guided IMRT preserves sexual function in men after prostatectomy

Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

3 Nov 2010

Staff member of U.S. preventive services task force quits over cancelled meeting

A member of the support staff for the United States Preventive Services Task Force has quit over the cancellation of a meeting scheduled for today and tomorrow at which the task force was due to vote on the controversial issue of prostate-cancer screening.

3 Nov 2010

$Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients$

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

2 Nov 2010

Men's Health News

Research may help develop new therapies for aggressive prostate cancer

New research shows psychoprophylaxis can help tocophobic men

New approach to treat castration resistant prostate cancer

Study confirms defect in sweat gland function as disease biomarker for XLHED

CMS to review cancer vaccine, analysis shows high Medicare drug spending not correlated with better care

Soy-based drug could prevent prostate cancer metastasis

Potential new biomarkers for very early prostate cancer

NCRI launches first virtual biobank for prostate cancer research

Radiotherapy can benefit men with high risk prostate cancer: Research

Testosterone treatment for frailty in older men lacks long term benefits

Level of prostate-specific protein after salvage radiation therapy predicts mortality and disease progression

Gene fusion prostate cancers susceptible to secondary mutations

Millennium and Takeda initiate TAK-700 Phase III clinical trial in advanced prostate cancer

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Medicare reimbursement cuts lead to decline in unnecessary or inappropriate care

EUSA announces publication of PROSTASCINT imaging for prostate cancer in official journal of American Society

AHRQ study finds prostate cancer mortality rate declines by 45%

Image Guided IMRT preserves sexual function in men after prostatectomy

Staff member of U.S. preventive services task force quits over cancelled meeting

Hypofractionated IMRT therapy does not increase side effects in prostate cancer patients

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News